• Directory of Taiwan

Lung Cancer Therapeutic Market Driven By Rising Number of Smokers And Launch of Innovative Drugs

  132, in its upcoming report titled, “Global Lung Cancer Therapeutics Market Trends, Applications, Analysis, Growth, and Forecast to 2027”, offers in-depth insights, revenue details, and other vital information regarding the global lung cancer therapeutics market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report also offers insightful and detailed information regarding the various key players operating in the global lung cancer therapeutics market, and their financials, apart from strategies, acquisitions & mergers, and market footprint. The global lung cancer therapeutics market has been segmented on the basis of cell type, and region.

Lung cancer is one of the most common cancer in the world. It’s a cancer that begins in the lungs and most often occurs in the people who smoke. Excessive smoking, this may be in the form of active or passive, tobacco intake, high level of pollution, radiations, and exposure increases the risk of lung cancer. Symptoms of lung cancer are cough that doesn’t go away and becomes worst day by day, wheezing, shortness of breath, constant chest pain, loss of appetite or weight loss, swelling of neck and face, and bloody mucus. This disease is diagnosed by using physical exam, imaging and lab test.

Some of the factors that support growth of the global lung cancer therapeutics market are rising number of smokers, launch of innovative drugs, new radiation therapies. In addition to this, constant exposure of asbestos, rising geriatric population and rise in prevalence of unhealthy life styles are also few factors that driving the global lung cancer therapeutic market. Availability of generic drugs, poor cancer diagnostic facilities in emerging countries, high cost of drugs and adverse effect of radiation and chemotherapy are factors likely to restrain the global lung cancer therapeutics market during the forecast period. However, government funding in the field of research and development of new drugs and increasing pollution due to rapid industrialization are some of the reasons driving growth of this market.

North America and Europe dominates the global lung cancer therapeutic market. Asia Pacific is projected to foresee the highest growth rate in the global lung cancer therapeutics market, due to rising prevalence of this disease and increasing health awareness. Europe accounts the second largest market after North America.

Global Lung Cancer Therapeutic Market Segmentation:

Global lung cancer therapeutic market segmentation by cell type:

Small cell lung cancer
Non-small cell lung cancer (Adenocarcinoma, large-cell carcinoma and squamous cell carcinoma.

Global lung cancer therapeutic market segmentation by region:

North America
Asia Pacific
Latin America
Middle East & Africa

Request For Sample Copy Of The Report Before Buying:

Key Players:

AstraZeneca Plc
GlaxoSmithkline Plc
Hoffmann-La Roche Ltd
Eli Lilly and company
Boehringerlngelheim GmbH
Pfizer Inc.
Agennix AG